128 related articles for article (PubMed ID: 33663040)
21. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
Pan Y; Jiao J; Zhou C; Cheng Q; Hu Y; Chen H
Pathobiology; 2010; 77(6):283-8. PubMed ID: 21266826
[TBL] [Abstract][Full Text] [Related]
22. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
[TBL] [Abstract][Full Text] [Related]
23. [Expression of THY1 gene in epithelial ovarian cancer].
Zeng LQ; Peng ZL; Duan ZL
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):118-20. PubMed ID: 19538887
[TBL] [Abstract][Full Text] [Related]
24. High Frequency of
Ishibashi T; Nakayama K; Razia S; Ishikawa M; Nakamura K; Yamashita H; Dey P; Iida K; Kurioka H; Nakayama S; Otsuki Y; Ishikawa N; Kyo S
Diagnostics (Basel); 2019 Dec; 10(1):. PubMed ID: 31892193
[TBL] [Abstract][Full Text] [Related]
25. MORPHOPHENOTYPIC CHARACTERISTICS OF OVARIAN SEROUS BORDERLINE TUMORS.
Munjishvili V; Barabadze E; Musashvili T; Gachechiladze M; Burkadze G
Georgian Med News; 2019 May; (290):20-25. PubMed ID: 31322508
[TBL] [Abstract][Full Text] [Related]
26. Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
Qiu C; Lu N; Wang X; Zhang Q; Yuan C; Yan S; Dongol S; Li Y; Sun X; Sun C; Zhang Z; Zheng W; Kong B
Gynecol Oncol; 2017 Dec; 147(3):634-641. PubMed ID: 28965696
[TBL] [Abstract][Full Text] [Related]
27. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
[TBL] [Abstract][Full Text] [Related]
28. [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance].
Shao SL; Cai Y; Wang QH; Yan LJ; Zhao XY; Wang LX
Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):697-700. PubMed ID: 18246802
[TBL] [Abstract][Full Text] [Related]
29. Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer.
Song IH; Kim KR; Lim S; Kim SH; Sung CO
Pathol Res Pract; 2018 Oct; 214(10):1564-1571. PubMed ID: 30082157
[TBL] [Abstract][Full Text] [Related]
30. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
[TBL] [Abstract][Full Text] [Related]
31. Autoimplants in serous borderline tumors of the ovary: a clinicopathologic study of 30 cases of a process to be distinguished from serous adenocarcinoma.
Rollins SE; Young RH; Bell DA
Am J Surg Pathol; 2006 Apr; 30(4):457-62. PubMed ID: 16625091
[TBL] [Abstract][Full Text] [Related]
32. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors.
Němejcová K; Šafanda A; Bártů MK; Michálková R; Drozenová J; Fabian P; Hausnerová J; Laco J; Matěj R; Méhes G; Škapa P; Stružinská I; Dundr P
Diagn Pathol; 2023 Feb; 18(1):32. PubMed ID: 36855066
[TBL] [Abstract][Full Text] [Related]
33. Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution.
Okoye E; Euscher ED; Malpica A
Am J Surg Pathol; 2016 May; 40(5):627-35. PubMed ID: 26900814
[TBL] [Abstract][Full Text] [Related]
34. Biological markers in pT1 and pT2 ovarian cancer with lymph node metastases.
Concin N; Hefler L; van Bavel J; Mueller-Holzner E; Zeimet A; Daxenbichler G; Speiser P; Hacker N; Marth C
Gynecol Oncol; 2003 Apr; 89(1):9-15. PubMed ID: 12694648
[TBL] [Abstract][Full Text] [Related]
35. MR imaging findings of low-grade serous carcinoma of the ovary: comparison with serous borderline tumor.
Kawaguchi M; Kato H; Hatano Y; Tomita H; Hara A; Suzui N; Miyazaki T; Furui T; Morishige KI; Matsuo M
Jpn J Radiol; 2020 Aug; 38(8):782-789. PubMed ID: 32246351
[TBL] [Abstract][Full Text] [Related]
36. Low-grade Serous Neoplasia of the Female Genital Tract.
Folkins AK; Longacre TA
Surg Pathol Clin; 2019 Jun; 12(2):481-513. PubMed ID: 31097112
[TBL] [Abstract][Full Text] [Related]
37. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
38. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
[TBL] [Abstract][Full Text] [Related]
39. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
40. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).
Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
J Ovarian Res; 2017 Jan; 10(1):7. PubMed ID: 28122595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
